The company has a team of scientists and advisors who have established scalable manufacturing approaches for production of the secretome product, which is a platform technology comprised of naturally therapeutic components including proteins, exosomes, and microRNAs. Cell Care is currently developing this technology to treat severe inflammatory and degenerative eye diseases, with a focus on diabetic macular edema, the leading cause of vision loss in working age adults.